Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL
Authors:
- Lisa M. GreeneLGLisa M. Greene
- Susan LedwidgeSLSusan Ledwidge
- Giuseppe CampianiGCGiuseppe Campiani
- Vito NacciVNVito Nacci
- Mark LawlerMLMark Lawler
- D. Clive WilliamsDWD. Clive Williams
- Daniela M. ZistererDZDaniela M. Zisterer
- 1 September 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 310 (3) , 1084-1095
Abstract
Overexpression of the Bcl-2 proto-oncogene in tumor cells confers resistance against chemotherapeutic drugs. In this study, we describe how the novel pyrrolo-1,5-benzoxazepine compound 7-[{dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) selectively induces apoptosis in Bcl-2-overexpressing cancer cells, whereas it shows no cytotoxic effect on normal peripheral blood mononuclear cells. PBOX-6 overcomes Bcl-2-mediated resistance to apoptosis in chronic myelogenous leukemia (CML) K562 cells by the time- and dose-dependent phosphorylation and inactivation of antiapoptotic Bcl-2 family members Bcl-2 and Bcl-XL. PBOX-6 also induces Bcl-2 phosphorylation and apoptosis in wild-type T leukemia CEM cells and cells overexpressing Bcl-2. This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis. In addition, PBOX-6 induces Bcl-2 phosphorylation and apoptosis in wild-type Jurkat acute lymphoblastic leukemia cells and cells overexpressing Bcl-2. However, Jurkat cells containing a Bcl-2 triple mutant, whereby the principal Bcl-2 phosphorylation sites are mutated to alanine, demonstrate resistance against Bcl-2 phosphorylation and apoptosis. PBOX-6 also induces the early and transient activation of c-Jun NH2-terminal kinase (JNK) in CEM cells. Inhibition of JNK activity prevents Bcl-2 phosphorylation and apoptosis, implicating JNK in the upstream signaling pathway leading to Bcl-2 phosphorylation. Collectively, these findings identify Bcl-2 phosphorylation and inactivation as a critical step in the apoptotic pathway induced by PBOX-6 and highlight its potential as an effective antileukemic agent.Keywords
This publication has 37 references indexed in Scilit:
- Activation of the c-Jun N-terminal Kinase (JNK) Signaling Pathway Is Essential during PBOX-6-induced Apoptosis in Chronic Myelogenous Leukemia (CML) CellsJournal of Biological Chemistry, 2002
- Transient Activation of Jun N-terminal Kinases and Protection from Apoptosis by the Insulin-like Growth Factor I Receptor Can Be Suppressed by DicumarolJournal of Biological Chemistry, 2001
- Bcl-2 Prevents Bax Oligomerization in the Mitochondrial Outer MembraneJournal of Biological Chemistry, 2001
- Vinblastine-induced Phosphorylation of Bcl-2 and Bcl-XL Is Mediated by JNK and Occurs in Parallel with Inactivation of the Raf-1/MEK/ERK CascadeJournal of Biological Chemistry, 2000
- The Putative Pore-Forming Domain of Bax Regulates Mitochondrial Localization and Interaction with Bcl-XLMolecular and Cellular Biology, 2000
- Quinone Reductase Inhibitors Block SAPK/JNK and NFκB Pathways and Potentiate ApoptosisJournal of Biological Chemistry, 1999
- Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosisThe EMBO Journal, 1998
- Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xLOncogene, 1998
- Molecular Ordering of the Cell Death PathwayJournal of Biological Chemistry, 1996
- Inactivation of Bcl-2 by phosphorylation.Proceedings of the National Academy of Sciences, 1995